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Abstract 
LDH is commonly used in human cancer patients for prognostic purposes. Aim of this 
study was to determine the magnitude of serum LDH elevation in dogs with cancer 
compared to healthy dogs and dogs with non-neoplastic disease, and to verify whether it 
may support the diagnosis of specific malignancies. 128 healthy dogs, 211 diseased 
dogs and 188 cancer dogs were enrolled. Dogs with cancer had significantly higher 
LDH than diseased (P<0.001) and healthy dogs (P<0.001), but large overlap was found. 
Dogs with lymphoma showed significantly higher LDH compared to dogs with 
carcinoma (P<0.001) or mast cell tumor (MCT; P<0.05) but not compared to other 
malignancies. When considering lymphoma and MCT, LDH levels were not different 
between early and advanced clinical stages. Measuring LDH levels may not be useful as 
a screening tool for cancer detection. More studies are needed to define its role in 
specific tumors. 
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Introduction 
Lactate dehydrogenase (LDH), which is expressed as 5 isoenzymes, is an ubiquitous 
glycolytic enzyme catalysing the final step in the glycolytic metabolism, by converting 
lactate to pyruvate thereby producing cellular energy.1 In people, increased LDH 
activity has been found in patients with myocardial or pulmonary infarction, hepatic 
disorders, haemolysis, and myopathy.2,3 Additionally, LDH is one of the most common 
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enzymes used in cancer patients for prognostic purposes, as its increase reflects tumor 
burden and treatment response. Indeed, LDH is considered as an important prognostic 
marker in lymphoma,4,5 leukemia,6,7 germ cell tumors,8 and melanoma,9,10 among 
others. Interestingly, serum measurement of LDH also helps in differentiating cancer 
from benign neoplasia, including uterine leiomyosarcoma from leiomyoma,11 and 
ovarian carcinoma from benign epithelial ovarian tumors.12 
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In veterinary medicine, early detection of cancer is often challenging, partly due to the 
lack of adequate tumor markers. Thus, the diagnosis of cancer relies on tissue biopsy in 
the majority of cases.  
By definition, tumor markers are biologic substances produced by neoplastic cells or by 
the host in response to the cancer; they are typically secreted into bloodstream, urine, 
stool and other body fluids, and can be detected by several methods.13 Measuring tumor 
marker levels in addition to routine diagnostic tests may be useful to identify some types 
of cancer.14,15 Apart from diagnosis, tumor markers may also reflect the extent of 
cancer, predict the response to therapy, or facilitate the identification of recurrence 
during follow-up.13 
Little research about LDH and cancer has been carried out in veterinary medicine. 
According to the literature, LDH increases in canine and feline lymphoma,16,17,30,31 the 
pathogenesis of which remains undetermined. For other specific tumors, including 
carcinomas and sarcomas, information are not yet available. 
Altough occasionally a higher specificity of LDH in neoplasias is found if the 
isoenzymes are assessed separately,5,7,16 total LDH measurement is sometimes 
preferred.17,33While total LDH levels generally reflect presence of tissue damage, 
measurement of individual isoenzymes may give a clue on which organ or tissue is 
damaged. 
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Aim of this study was to determine whether elevation of total LDH occurred in dogs 
with cancer compared to healthy dogs and dogs with non-neoplastic disease, and to 
evaluate if the enzyme may be useful in supporting the diagnosis of specific 
malignancies. 
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Materials and methods 
 
Selection of dogs 
Healthy dogs presenting for periodical examination (including general health check 
and/or regular vaccination), untreated dogs with various non-neoplastic diseases, and 
untreated dogs with cancer, admitted to the Clinica Veterinaria L’Arca, were 
prospectively enrolled.  
For each included case, signalment information was obtained. Dogs with non-neoplastic 
diseases were presented with a variety of clinical signs; they had no evidence of 
malignancy based on results of physical examination, blood work, thoracic radiography 
and/or abdominal ultrasound. 
All cancer cases were diagnosed by means of cytology and flow cytometry (liquid 
tumors) or histopathology (solid tumors) and underwent complete staging work-up, 
including thoracic radiology, abdominal ultrasound, and evaluation of the regional 
lymph node. For hematopoietic cancer, histiocytic disease and mast cell tumors, 
cytological samples of the bone marrow were also obtained.  
 
LDH evaluation 
At presentation, blood from the jugular vein was sampled after 12-hours fasting, and the 
serum obtained by centrifugation was processed within 30 minutes.  
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Given the fact that all kind of tumors could be enrolled, either localized and metastatic, 
total serum LDH measurement was preferred over isoenzymes. For all dogs, total LDH 
levels were determined with a commercial assay (kinetic UV method Pyruvate-Lactate, 
Biogamma SRL, Rome, Italy) according to the manufacturer. The normal range of total 
serum LDH at our laboratory is 10-280 U/l. For each included dog, the following 
haematological parameters were also recorded: packed cell volume (PCV), albumin, 
creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and 
alkaline phosphatase (ALP). 
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Statistical analysis 
Comparison among LDH levels in dogs with cancer and healthy or diseased dogs was 
calculated with one-way ANOVA followed by Tukey’s multiple comparison test. The 
same analysis was used to compare LDH levels among specific tumors; types of cancer 
were included if represented by at least 10 cases. To assess whether tumor stage, which 
generally reflects cancer extension, is associated with LDH levels, concentrations were 
compared between stages for selected tumors, including lymphoma and mast cell tumor 
with the T-test or Mann-Whitney test. For lymphoma cases, comparison was made 
between stage I-IV and stage V. Stages I-IV were grouped together because biologically 
less aggressive than stage V (meaning bone marrow involvement). For mast cell tumors, 
comparison was made between stage II and IV grouped together (metastatic to regional 
lymph nodes and distant sites, respectively) and stage I and III (non metastatic). 
Because LDH levels may be affected by several factors in humans, including anemia, 
liver disease and renal failure,2,3 possible relationships between LDH levels and 
laboratory parameters, such as PCV, albumin, creatinine, ALT, AST or ALP, were 
investigated in all dogs with Pearson correlation coefficient. Because aging dogs are 
more likely to be affected by a disease, the correlation was also investigated between 
 6 
LDH levels and age. Significance was considered for p < 0.05. Statistical analysis was 
performed with GraphPad Prism version 4.0 (GraphPad Software, San Diego, CA, 
USA). 
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Results 
 
Healthy dogs 
One-hundred twenty-eight healthy dogs were enrolled. Median age was 7 years (range, 
0.3 to 18 years). There were 83 males (69 intact, 14 neutered) and 45 females (23 intact, 
22 spayed). Regarding breed, there were 58 mixed breeds and 70 pure breeds, with 
German shepherd dogs (11/70, 15.7%), Labrador retrievers (9/70, 12.9%) and Yorkshire 
terriers (6/70, 8.6%) being more frequent. 
At presentation, mean LDH level was 142.3 ± 79.5 U/l (range, 22 to 523 U/l). One-
hundred twenty (93.8%) dogs had normal LDH, whereas 8 (6.2%) dogs had elevated 
LDH. 
 
Dogs with non-neoplastic disease 
Two-hundred eleven diseased dogs were enrolled. Median age was 9 years (range, 0.1 
to 18 years). There were 114 males (101 intact, 13 neutered) and 97 females (51 intact, 
46 spayed). Regarding breed, there were 97 mixed breeds and 114 pure breeds, with 
Yorkshire terriers (20/114, 17.5%), Labrador retrievers (17/114, 14.9%), German 
shepherd dogs (16/114, 14.0%) and Cocker spaniels (7/114, 6.1%) being more frequent. 
The most common disorders were: urogenital diseases (n=28), gastroenteritis (n=25), 
dermatologic diseases (n=22), leishmaniosis (n=19), hepatopathies (n=15), cardiac 
diseases (n=13), arthrosis (n=11), epilepsy (n=8), diabetes mellitus (n=7), ehrlichiosis 
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(n=7), immune-mediated haemolytic anemia (n=6), hydrocephalus (n=3), 
hypothyroidism (n=3), pancreatitis (n=3), hemophagocytic syndrome (n=3), systemic 
inflammatory response syndrome (n=3), tracheal collapse (n=2), reactive histiocytosis 
(n=2), hypovolemic shock (n=2).  
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When considering specific diseases, dogs with pyometra had more often elevated LDH 
levels (6/9, 66.7%). Unlike previous experience in human medicine, here only 5 
(38.5%) out of the 13 dogs with cardiac diseases and 5 (33.3%) out of the 15 dogs with 
hepatopathies had increased LDH levels.  
Among dogs with leishmaniosis and ehrlichiosis, only 2 out of 19 (10.5%) and 1 out of 
7 (14.3%), respectively, had increased LDH levels at presentation. All of them showed 
generalized peripheral lymphadenopathy, a clinical finding which is typical of 
multicentric lymphoma as well. 
At presentation, mean LDH level was 232.8 ± 202.9 U/l (range, 33 to 1800 U/l). One-
hundred sixty-two (76.8%) dogs had normal LDH, whereas 49 (23.2%) dogs had 
elevated LDH.  
 
Dogs with cancer 
One-hundred and eighty-eight dogs with cancer were included. Median age was 10 
years (range, 0.6 to 18 years). There were 96 males (87 intact, 9 neutered) and 92 
females (47 intact, 45 spayed). Regarding breed, there were 76 mixed breeds and 112 
pure breeds, with Rottweilers (14/112, 12.5%), German shepherd dogs (11/112, 9.8%), 
Yorkshire terriers (9/112, 8.0%), Labrador retrievers (8/112, 7.1%), cocker spaniels and 
boxers (6/112, 5.4%, each) being more frequent. 
The following tumors were diagnosed: lymphoma (n=55), mammary carcinoma (n=17), 
mast cell tumor (n=17), histiocytic sarcoma (n=11), pituitary dependent 
hyperadrenocorticism (n=11), hemangiosarcoma (n=10), osteosarcoma (n=9), soft tissue 
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spindle cell tumors (n=6), mammary inflammatory carcinoma (n=4), prostatic 
carcinoma (n=3), tonsilar carcinoma (n=3), chronic lymphocytic leukemia (n=3), Sertoli 
cell tumor (n=3), hepatocellular carcinoma (n=2), perianal carcinoma (n=2), digital 
squamous cell carcinoma (n=2), bladder urothelial carcinoma (n=2), acute 
lymphoblastic leukemia (n=2), intestinal leiomyosarcoma (n=2), oral fibrosarcoma 
(n=2), carcinoid (n=2), adrenal dependent hyperadrenocorticism (n=2), and one each of 
the following: bladder adenocarcinoma, perianal adenoma, bronchioloalveolar 
carcinoma, renal carcinoma, anal sac carcinoma, nasal carcinoma, oral squamous cell 
carcinoma, aortic chemodectoma, cholangiocarcinoma, gastrinoma, Leydig cell tumor, 
histiocytoma, oral melanoma, digital melanoma, multiple myeloma, thymoma, 
meningioma, and venereal transmissible tumor. 
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At presentation, mean LDH level for all cancer cases was 341.6 ± 342.5 U/l (range, 13 
to 3325 U/l). One-hundred and six (56.4%) dogs had normal LDH, whereas 82 (43.6%) 
dogs had elevated LDH.  
Regarding lymphoma cases, mean LDH level was 511.1 ± 450.9 U/l (range, 86 to 3325 
U/l). Among them, 43 of 55 (78.2%) dogs had elevated LDH levels at diagnosis. When 
considering clinical stage, dogs with stage I-IV (n = 32) disease had mean LDH level of 
430.8 ± 450.9 U/l (range, 86 to 1132 U/l), whereas dogs with stage V (n = 23) disease 
had mean LDH level of 622.7 ± 633.7 U/l (range, 120 to 3325 U/l). 
Regarding mast cell tumors, mean LDH level was 205.6 ± 210.2 U/l (range, 40 to 817 
U/l). Among these cases, 3 of 17 (17.6%) had elevated LDH at presentation. When 
considering clinical stage, dogs with stage I and III disease (n = 11) had mean LDH 
level of 175.6 ± 162.4 U/l (range, 72 to 644 U/l), whereas dogs with stage II and IV 
disease (n = 6) had mean LDH level of 260.7 ± 288.1 U/l (range, 40 to 817 U/l). 
Regarding dogs with histiocytic sarcoma, mean LDH level was 344.4 ± 247.3 U/l 
(range, 73 to 693 U/l). Among them, 5 of 11 (45.5%) had elevated LDH at presentation.  
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Comparison among groups 
Mean LDH concentration was significantly higher in tumor-bearing dogs than either 
healthy dogs or dogs with non-tumoral diseases. The latter group had significantly 
higher levels than healthy dogs (fig. 1). 
Considering specific tumors, mean LDH levels were significantly higher for dogs with 
lymphoma than either dogs with carcinoma or mast cell tumor (Figure 2). Differences 
were not observed with sarcoma, histiocytic sarcoma, and hyperadrenocorticism. 
LDH levels were similar between dogs with lymphoma stage V and I-IV, or between 
dogs with mast cell tumor stage II or IV and I or III. 
Considering the whole population of dogs, a significant positive correlation was found 
between LDH levels and age (r= 0.15; CI95%= 0.07 − 0.24), and a negative correlation 
between LDH and PCV (r= -0.10; CI95%= -0.18 − -0.02) or albumin (r= -0.18; CI95%= 
-0.26 − -0.10) (Figure 3). Correlations were not found with ALT, AST or ALP (data not 
shown). 
 
 
Discussion 
Early detection of cancer is still very challenging. Beside ultrasound, CT scan, magnetic 
resonance, and newer imaging techniques, such as positron emission tomography, are 
used for tumor staging and are considered helpful for early diagnosis.18 Despite 
progresses, the minimum tumor size enabling detection with the afore-mentioned 
techniques is represented by 109 cells, a point at which successful intervention is often 
not possible.19 
Little data has been published in the veterinary literature on circulating diagnostic tumor 
markers, including acute phase proteins,20-24 alpha-fetoprotein,25-27 alkaline 
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phosphatase,28,29 thymidine kinase,30,31 and lipid-associated sialic acid,32 yet their biologic 
significance has not been completely elucidated.  
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Determination of serum LDH levels is a well-known diagnostic tool in human 
oncology,4-10 and Occasionally, measurement of LDH levels failed to show specificity 
in human cancer patients. For instance, high LDH levels in melanoma patients do not 
necessarily indicate a more advanced disease, thereby possibly leading to false-positive 
results if not cautiously interpreted during initial staging work-up.34  
High LDH levels were also reported in dogs and cats with lymphoma.16,17,30,31,35 
In this study, we assessed LDH levels in dogs with various types of cancer. Values 
recorded in dogs considered to be clinically healthy and in those affected by non-
neoplastic diseases served as controls. Dogs with cancer were found to have 
significantly higher serum LDH levels than dogs in the healthy control group (P<0.001) 
and dogs with non-neoplastic diseases (P<0.001). Altogether, LDH was found to be 
increased in 43.6% of cancer cases. Among them, dogs with lymphoma had more often 
elevated LDH levels (78.2%) at presentation. Levels of LDH were higher in lymphoma 
than in either carcinoma (P<0.001) or mast cell tumors (P<0.05).  
Although mean LDH levels were significantly higher in cancer patients (341.6 ± 342.5 
U/l) than in dogs with non-neoplastic disease (232.8 ± 202.9 U/l) or in healthy 
individuals (142.3 ± 79.5 U/l), considerable overlap existed between groups, likely 
preventing its use as useful marker for tumor detection. In addition, about 50% of cases 
with proven malignancy had no LDH elevation at presentation, whereas 23.2% of dogs 
with non-neoplastic disease and 6.2% of healthy dogs had increased LDH, thereby 
indicating that a cut-off point discerning tumor-bearing negative and positive cases 
cannot be identified. 
Also in the case of tumor types, LDH levels were largely overlapping. Thus, measuring 
activity of the enzyme has limited usefulness, especially in tumor-bearing dogs with 
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normal LDH levels or when a tumor has been confirmed but its origin has not been 
clarified. 
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We also analyzed the role of LDH in different stages of lymphoma and mast cell tumors 
(early versus metastatic). Its level was not found to be different between lower and 
higher stages. It is possible that, for mast cell tumors, the low proportion of metastatic 
cases (6/17; 35.3%) prevented a significant difference to emerge. The contrary may hold 
true for lymphoma, since there were no early stage (I-II) lymphoma cases. 
Alternatively, LDH is not useful in these patients to differentiate between 
metastatic/advanced and non-metastatic/early cancer.  
To the authors’ knowledge, there are no studies exploring the diagnostic utility of LDH 
in differentiating benign from malignant disease. Beside multicentric lymphoma, further 
pathological conditions frequently associated with generalized lymphadenopathy 
include leishmaniosis, ehrlichiosis, bacterial, viral and fungal infections. Cytological 
evaluation of the enlarged lymph nodes by a skilled clinical pathologist leads very often 
to the diagnosis of lymphoma. Routine blood work, including assessment of serum 
globulins, may provide additional valuable diagnostic information. In this case series, 
there were 19 dogs with leishmaniosis and 7 dogs with ehrlichiosis, all presenting with 
enlargement of the peripheral lymph nodes. An interesting finding was that 78.2% of 
dogs with lymphoma had increased LDH levels, whereas only 10.5% and 14.3% of dogs 
with leishmaniosis and ehrlichiosis, respectively, showed increased concentration. Thus, 
LDH measurement may be useful in the initial work-up in selected cases, more likely 
suggesting a malignant etiology if increased. 
Not unexpected, a correlation was found between age and LDH levels, likely due to the 
fact that older dogs are more likely to develop diseases. The negative correlation 
observed with PCV or albumin concentrations may suggest a shift towards anaerobic 
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glycolysis in tissues, at least in part due to hypoxemia.1 However, it must be noted that 
in each instance correlations were weak, questioning the value of the findings. 
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In conclusion, this study showed that LDH levels has limited use in differentiating dogs 
with cancer from healthy dogs and dogs with non-neoplastic disease, or among different 
tumors, because results largely overlap. Furthermore, in dogs with lymphoma and mast 
cell tumors, LDH does not help identifying early or advanced stage cancers. In selected 
cases, such as in dogs with enlarged lymph nodes due to lymphoma or leishmaniosis 
and ehrlichiosis, knowing LDH levels may help refining the diagnosis. More studies are 
needed to definitely clarify the role of LDH in dogs with lymphoma. 
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Abbreviated title: LDH and cancer 
Figure legends 
 
 
Figure 1. Serum levels of LDH measured in clinically healthy dogs, and dogs with non-tumoral 
disorders or with tumor. Scatter plot and mean values are reported. 
 
Figure 2. Serum levels of LDH measured in dogs with different tumors, including carcinoma, 
sarcoma, lymphoma, mastocytoma, histiocytic sarcoma and hyperadrenocorticism. Values are 
expressed as mean and standard deviation. 
 
Figure 3. Correlation between serum levels of LDH and age (A), PCV (B), and albumin 
concentration (C) in all dogs. Regression lines are plotted. 
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